

# Diagnosis And Treatment Of Patients With Primary And Metastatic Breast Cancer

## Breast Cancer: Specific Situations

© AGO e. V.  
in der DGGG e.V.  
sowie  
in der DKG e.V.

Guidelines Breast  
Version 2017.1

# Breast Cancer: Specific Situations

© AGO e. V.  
in der DGGG e.V.  
sowie  
in der DKG e.V.

Guidelines Breast  
Version 2017.1

➤ **Versions 2005-2016:**

**Dall / Fehm / Fersis / Friedrich / Gerber /  
Göhring / Harbeck / Huober / Janni / Loibl /  
Lück / Lux / Maass / Mundhenke / Oberhoff /  
Rody / Scharl / Schneeweiss / Solomayer /  
Thomssen**

➤ **Version 2017:**  
**Schütz / Sinn**

Further  
Information

References

# Breast Cancer: Specific Situations

- **Young patients**
- **Pregnancy- and breast-feeding-associated BC**
- **Elderly patients**
- **Male patients**
- **Inflammatory BC**
- **Occult Breast Cancer (Cancer of unknown primary – axillary CUP)**
- **Paget's disease**
- **Malignant and Borderline Phyllodes Tumor**
- **Angiosarcoma**
- **Breast Implant-Associated Anaplastic Large-Cell Lymphoma (BIA-ALCL)**

# Breast Cancer in Young Women $\leq 35$ Years

Oxford / AGO  
LoE / GR

---

- |  |           |          |           |
|--|-----------|----------|-----------|
| ➤ <b>Aggressive biological behavior with worse prognosis</b>                       | <b>2a</b> | <b>B</b> |           |
| ➤ <b>Surgery like patients <math>\geq 35</math> y</b>                              | <b>2b</b> | <b>B</b> | <b>+</b>  |
| ➤ <b>Guidelines adapted (neo-)adjuvant systemic treatment (see chapters there)</b> | <b>1b</b> | <b>A</b> | <b>++</b> |
| ➤ <b>GnRHa as ovarian protection (see chapter gyn. problems)</b>                   | <b>1b</b> | <b>B</b> | <b>+</b>  |
| ➤ <b>Genetic and fertility counseling</b>  | <b>2b</b> | <b>B</b> | <b>++</b> |
| ➤ <b>Contraception counseling</b>  | <b>2b</b> | <b>B</b> | <b>++</b> |

© AGO e. V.  
in der DGGG e.V.  
sowie  
in der DKG e.V.

Guidelines Breast  
Version 2017.1

[www.ago-online.de](http://www.ago-online.de)

Further  
Information

References

# Breast Cancer During Pregnancy\* or Breast Feeding – Diagnostics and Surgery



© AGO e. V.  
in der DGGG e.V.  
sowie  
in der DKG e.V.

Guidelines Breast  
Version 2017.1

	Oxford / AGO LoE / GR		
➤ <b>Breast imaging &amp; biopsy like in non-pregnant</b>	4	C	++
➤ <b>Staging if indicated (Bone scan after delivery)</b>	5	D	+
➤ <b>Surgery like in non-pregnant patients</b>	4	C	++
➤ <b>Sentinel node excision (technetium only)</b>	4	C	+
➤ <b>SLNE during 1<sup>st</sup> trimester</b>	5	D	+/-
➤ <b>Sensitivity and specificity not established (during lactation); breast feeding should be avoided for 24 hrs</b>	4	C	++
➤ <b>Blue dye (has not been tested in pregnant animals or humans)</b>	4	C	--

www.ago-online.de

Further  
Information

References

FORSCHEN  
LEHREN  
HEILEN

\* Participation in register study recommended

# Breast Cancer During Pregnancy - (Neo-)adjuvant Therapy -

Oxford / AGO

LoE / GR

➤ Radiation therapy during pregnancy	4	C	-
➤ (Neo-)adjuvant chemotherapy only after first trimester (indication as in non-pregnant)			++
➤ Anthracyclines: AC, EC	2b	B	++
➤ Taxanes	2b	B	+
➤ MTX (e.g. CMF)	4	D	--
➤ Endocrine treatment	4	D	--
➤ HER2-neu targeted treatment	3a	C	--
➤ Bisphosphonates, denosumab	4	D	-

© AGO e. V.  
in der DGGG e.V.  
sowie  
in der DKG e.V.

Guidelines Breast  
Version 2017.1

www.ago-online.de

Further  
Information

References

# Breast Cancer During Pregnancy\* - Delivery and Breast-Feeding-

Oxford / AGO  
LoE / GR

- |   |  |             |           |
|---|--|-------------|-----------|
| ➤ | <b>Delivery should be postponed until sufficient fetal maturation (avoid iatrogenic prematurity)</b>                             | <b>2b C</b> | <b>++</b> |
| ➤ | <b>Termination of pregnancy does not improve maternal outcome</b>  | <b>3b C</b> |           |
| ➤ | <b>Delivery mode like in healthy women, avoid delivery <math>\leq 3</math> weeks from last cycle of chemotherapy</b>             | <b>4 C</b>  | <b>++</b> |
| ➤ | <b>If further systemic therapy is needed after delivery, breast feeding may be contra-indicated depending on drug toxicities</b> | <b>5 D</b>  | <b>++</b> |

© AGO e. V.  
in der DGGG e.V.  
sowie  
in der DKG e.V.

Guidelines Breast  
Version 2017.1

www.ago-online.de

Further  
Information

References

FORSCHEN  
LEHREN  
HEILEN

\* Participation in register study recommended

# Breast Cancer and Pregnancy - Family Planning-

Oxford / AGO  
LOE / GR

- |   |  |          |          |           |
|---|--|----------|----------|-----------|
| ➤ | <b>After breast cancer diagnosis reproductive techniques can be used to induce pregnancy</b>   | <b>5</b> | <b>D</b> | <b>++</b> |
| ➤ | <b>Success rates for getting pregnant and for deliver a child are lower in breast cancer patients in comparison to non-cancer patients</b> | <b>5</b> | <b>D</b> | <b>++</b> |
| ➤ | <b>Breast cancer patients of reproductive age should be offered a fertility counseling before starting any kind of treatment</b>           | <b>5</b> | <b>D</b> | <b>++</b> |
| ➤ | <b>Breast cancer patients should not be advised against getting pregnant regardless of tumor's hormone receptor status</b>                 | <b>5</b> | <b>D</b> | <b>++</b> |

© AGO e. V.  
in der DGGG e.V.  
sowie  
in der DKG e.V.

Guidelines Breast  
Version 2017.1

www.ago-online.de

Further  
Information

References



# Pregnancy Associated Breast Cancer\*: Outcome

Oxford

LoE

---

➤ **BC during pregnancy / lactation**

- Adequate treatment is essential

3a

➤ **Pregnancy and lactation after BC**

- Outcome not compromised

3a

© AGO e. V.  
in der DGGG e.V.  
sowie  
in der DKG e.V.

Guidelines Breast  
Version 2017.1

[www.ago-online.de](http://www.ago-online.de)

Further  
Information

References

**FORSCHEN  
LEHREN  
HEILEN**

\* Participation in register study recommended

# Geriatric Assessment

- **No specific algorithm is available**
- **Ability to tolerate treatment varies greatly („functional reserve“)**
- **Comprehensive geriatric assessment (CGA) describes a multidisciplinary evaluation of independent predictors of morbidity and mortality for older individuals**
  - **Physical, mental, and psycho-social health**
  - **Basic activities of daily living (dressing, bathing, meal preparation, medication management, etc.)**
  - **Living arrangements, social network, access to support services**
- **Assessment tools:**
  - **Charlson Comorbidity Index (widely used; good predictor over a 10-year period)**
  - **12 prognostic indicators to estimate 4-year mortality risk**
  - **Short screening tests (more qualitative evaluation)**
  - **IADL (IADL = The Lawton Instrumental Activities of Daily Living Scale with 8 domains of function, that are measured), G8**
  - **Geriatric Prognostic Index (GPI), 3 parameters in oncological patients (psychological distress or acute disease, >3 prescribed drugs, neuropsychological problems)**

# Treatment for Fit Elderly Patients

(Life Expectancy > 5 yrs. and Acceptable Comorbidities)

Oxford / AGO  
LoE / GR

➤ <b>Clinical geriatric assessment</b>	<b>2b</b>	<b>B</b>	<b>++</b>
➤ <b>Treatment according to guidelines</b>	<b>2a</b>	<b>C</b>	<b>++</b>
➤ <b>Surgery similar to „younger“ age</b>	<b>2b</b>	<b>B</b>	<b>++</b>
➤ <b>Endocrine treatment (endocrine resp.)</b>	<b>1a</b>	<b>A</b>	<b>++</b>
➤ <b>Chemotherapy (standard regimens)</b>			
➤ <b>&lt; 70 years</b>	<b>1a</b>	<b>A</b>	<b>+</b>
➤ <b>&gt; 70 years (especially N+, ER/PgR-)</b>	<b>2a</b>	<b>C</b>	<b>+*</b>
➤ <b>Radiotherapy</b>	<b>1a</b>	<b>A</b>	<b>+</b>
➤ <b>Omit radiotherapy after BCT in low risk with endocrine treatment</b>	<b>1b</b>	<b>B</b>	<b>+</b>
➤ <b>Trastuzumab</b>	<b>2b</b>	<b>C</b>	<b>+</b>

\*Study participation recommended

# Treatment for Frail Patients (Life Expectancy <5 yrs, Substantial Comorbidities)

Oxford / AGO  
LoE / GR

---

- **Reduced standard treatment** **2b C ++**
  
- **Options extrapolated from trials in elderly:**
  - **No breast surgery  
(consider endocrine options)** **2b C +**
  - **No axillary clearing (≥ 60 y, cN0, rec.-pos)** **2b B +**
  - **No radiotherapy (≥ 65 y, pT1, pN0, rec.-pos)** **1b B ++**
  - **Hypofractionated radiotherapy** **2b B +**
  - **No chemotherapy if >70 years and negative  
risk-benefit analysis** **2b C +**

# Male Breast Cancer: Diagnostic Work-Up and Loco-Regional Therapy

© AGO e. V.  
in der DGGG e.V.  
sowie  
in der DKG e.V.

Guidelines Breast  
Version 2017.1

www.ago-online.de

Further  
Information

References

FORSCHEN  
LEHREN  
HEILEN

	Oxford / AGO LoE / GR		
➤ <b>Diagnostic work-up as in women</b>	4	C	+
➤ <b>Mammography</b>	3b	C	+/-
➤ <b>Ultrasound</b>	2b	B	++
➤ <b>Standard-surgery: Mastectomy</b>	4	C	++*
➤ <b>BCT is an option (tumor breast relation)</b>	4	C	+*
➤ <b>Sentinel-node excision (SNE)</b>	2b	B	+
➤ <b>Radiotherapy as in women (consider tumor breast relation!)</b>	4	C	+
➤ <b>Genetic counselling if <u>one</u> additional relative affected (breast/ovarian cancer)</b>	2b	B	++
➤ <b>Screening for 2<sup>nd</sup> malignancies according to guidelines</b>	GCP		++

\*Participation in register study recommended

# Male Breast Cancer: Systemic Therapy

**Oxford / AGO  
LoE / GR**

- |   |           |          |            |
|---|-----------|----------|------------|
| ➤ <b>Adjuvant chemotherapy as in women</b>    | <b>2a</b> | <b>B</b> | <b>++</b>  |
| ➤ <b>HER2-targeted therapy</b>                | <b>5</b>  | <b>D</b> | <b>+*</b>  |
| ➤ <b>Endocrine therapy</b>                    | <b>4</b>  | <b>D</b> | <b>++</b>  |
| - <b>Tamoxifen</b>                            | <b>2b</b> | <b>B</b> | <b>++</b>  |
| - <b>Aromatase inhibitors (adjuvant)</b>      | <b>2b</b> | <b>B</b> | <b>-*</b>  |
| - <b>Aromatase inhibitors (metastatic BC)</b> | <b>4</b>  | <b>C</b> | <b>+/-</b> |
| - <b>GnRHa and AI (metastatic BC)</b>         | <b>4</b>  | <b>C</b> | <b>+*</b>  |
| - <b>Fulvestrant (metastatic BC)</b>          | <b>4</b>  | <b>C</b> | <b>+/-</b> |
| ➤ <b>Palliative chemotherapy as in women</b>  | <b>4</b>  | <b>C</b> | <b>++</b>  |

**\*Participation in register study recommended**

© AGO e. V.  
in der DGGG e.V.  
sowie  
in der DKG e.V.

Guidelines Breast  
Version 2017.1

www.ago-online.de

Further  
Information

References

**FORSCHEN  
LEHREN  
HEILEN**

# Benefit from Trimodal Treatment in Inflammatory Breast Cancer

Median survival probability		
Trimodal therapy	72 months	p<0.05
Surgery alone	26 months	

Overall survival-probability (OS)	10 years-OS	5 years-OS
Trimodal therapy	55.4%	37.3%
Surgery & chemotherapy	42.9%	28.5%
Surgery & radiotherapy	40.7%	23.5%
Surgery alone		16.5%

Multivariate analysis of OS	Hazard Ratio	95% CI
Surgery & chemotherapy & RT (trimodal therapy)	1.00	-
Surgery & chemotherapy	1.64	1.46 to 1.84
Surgery & radiotherapy	1.47	0.96 to 2.24
Surgery alone	2.28	1.80 to 2.89

© AGO e. V.  
in der DGGG e.V.  
sowie  
in der DKG e.V.

Guidelines Breast  
Version 2017.1

www.ago-online.de

Further  
Information

References

FORSCHEN  
LEHREN  
HEILEN

# Inflammatory Breast Cancer (IBC, cT4d)

Oxford / AGO  
LOE / GR

- | ➤ Invasive BC and clinical signs of inflammation (e.g. $\geq 1/3$ of the breast affected) determine stage cT4d |    |   | ++  |
|--|----|---|-----|
| ➤ Staging  | 2c | B | ++  |
| ➤ Skin punch biopsy (at least 2; detection rate < 75%)   | 2c | B | +   |
| ➤ Neoadjuvant chemotherapy (regimens as in non-inflammatory BC)  | 2c | B | ++  |
| ➤ Adjuvant systemic treatment according to guidelines  | 2c | B | ++  |
| ➤ Mastectomy after chemotherapy  | 2c | B | ++  |
| ➤ Breast conserving therapy in case of pCR (individual)  | 2b | C | +/- |
| ➤ Sentinel excision only   | 3b | C | -   |
| ➤ Radiotherapy (PMRT)  | 2c | B | ++  |



# Axillary Metastasis in Occult Breast Cancer (Cancer of Unknown Primary – Axillary CUP)

- **Incidence: < 1% of metastatic axillary disease**
- **In > 95% occult breast cancer, < 5% other primary**
- **Immunohistology**
  - ER-positive: 55%**
  - HER2 3+: 35%**
  - Triple-negative: 38%**
- **Nodal status:**
  - 1 - 3 Ln-Met. in 48%**
  - > 3 Ln-Met in 52%**
- **Outcome similar or better than in breast cancer with similar tumor biology and tumor stage**

# Axillary Metastasis in Occult Breast Cancer (Axillary CUP) Imaging Diagnostics

Oxford / AGO  
LOE / GR

- |  |           |          |           |
|--|-----------|----------|-----------|
| ➤ <b>Mammography, Breast-ultrasound, Breast-MRI</b>  | <b>3</b>  | <b>B</b> | <b>++</b> |
| ➤ <b>Exclude contralateral cancer</b>  | <b>3</b>  | <b>B</b> | <b>++</b> |
| ➤ <b>Exclude non-breast malignancy, especially in case of TNBC (e.g. skin, female genital tract, lung, thyroid gland, stomach)</b> | <b>5</b>  | <b>D</b> | <b>++</b> |
| ➤ <b>Staging (CT thorax / abdomen, thyroid scintigraphy, HNT-exam)</b>   | <b>3</b>  | <b>B</b> | <b>++</b> |
| ➤ <b>PET / PET-CT</b>  | <b>3b</b> | <b>B</b> | <b>+</b>  |

© AGO e. V.  
in der DGGG e.V.  
sowie  
in der DKG e.V.

Guidelines Breast  
Version 2017.1

www.ago-online.de

Further  
Information

References

# Axillary Metastasis in Occult Breast Cancer (Axillary CUP) Pathology, Molecular Pathology

Oxford / AGO  
LOE / GR

- |  |          |
|--|----------|
| ➤ ER, PgR, HER2, GATA3   | 5 D ++   |
| ➤ Exclusion of other primary malignancies in case of triple-negative phenotype or unusual histology, e.g. lung, female genital tract, HNT tumors, neuroendocrine ca. | 5 D ++   |
| ➤ Gene expression profiling for determination or primary site (CUPprint, Pathwork, TOT, Theros CTID)   | 2c B +/- |
| ➤ NGS, epigenetics for determination of primary site (Panel-Sequencing, EPICup)  | 2c B +/- |
| ➤ Prognostic gene expression tests   | 5 D - -  |

© AGO e. V.  
in der DGGG e.V.  
sowie  
in der DKG e.V.

Guidelines Breast  
Version 2017.1

www.ago-online.de

Further  
Information

References

# Axillary Metastasis in Occult Breast Cancer (Axillary CUP) Therapy



Oxford / AGO  
LOE / GR

- |  |             |            |
|--|-------------|------------|
| ➤ <b>Axillary dissection</b>   | <b>3a C</b> | <b>++</b>  |
| ➤ <b>Mastectomy if breast MRI is negative</b>  | <b>3a C</b> | <b>-</b>   |
| ➤ <b>(Neo-) adjuvant systemic therapy according to breast cancer guidelines (AGO)</b>    | <b>5 D</b>  | <b>++</b>  |
| ➤ <b>Breast irradiation if breast MRI is negative</b>                                    | <b>3b C</b> | <b>+/-</b> |
| ➤ <b>Irradiation of regional lymph nodes according to breast cancer guidelines (AGO)</b> | <b>3b B</b> | <b>+</b>   |

© AGO e. V.  
in der DGGG e. V.  
sowie  
in der DKG e. V.

Guidelines Breast  
Version 2017.1

www.ago-online.de

Further  
Information

References

FORSCHEN  
LEHREN  
HEILEN

# Paget's Disease of the Breast

© AGO e. V.  
in der DGGG e.V.  
sowie  
in der DKG e.V.

Guidelines Breast  
Version 2017.1

- **Paget's disease of the breast is characterized by an intraepidermal tumor manifestation originating in intraductal or invasive breast cancer. Isolated Paget's disease of the nipple is more rarely seen, and less aggressive.**

## Feature

## Frequency

Presentation

Paget's disease with invasive Ca. (37 - 58%)  
Paget's disease mit DCIS (30 - 63%)  
Isolated Paget's disease (4 - 7%)  
Isolated Paget's disease with invasion (rare)

IHC

HER2-positive (83 - 97%)  
ER-positive (10 - 14%)  
AR-positive (71 - 88%)

Further  
Information

References

www.ago-online.de

# Paget's Disease of the Breast Diagnosis

Oxford / AGO  
LOE / GR

- |  |          |          |           |
|--|----------|----------|-----------|
| ➤ <b>Histological verification by skin biopsy</b>  |          |          | <b>++</b> |
| ➤ <b>Mammography, sonography</b>   | <b>4</b> | <b>D</b> | <b>++</b> |
| ➤ <b>MR of the breast if other imaging negative</b>  | <b>4</b> | <b>C</b> | <b>+</b>  |
| ➤ <b>Immunohistology (ER, PgR, HER2, Ck7)<br/>to detect benign and HER2-negative cases</b> | <b>5</b> | <b>D</b> | <b>++</b> |

© AGO e. V.  
in der DGGG e.V.  
sowie  
in der DKG e.V.

Guidelines Breast  
Version 2017.1

www.ago-online.de

Further  
Information

References

FORSCHEN  
LEHREN  
HEILEN

# Paget's Disease of the Breast Therapy

Oxford / AGO  
LOE / GR

- **Paget's disease with underlying disease (invasive breast cancer, DCIS)**
  - **Therapy according to standard of the underlying disease** 5 D ++
  - **Surgery must achieve R0** 1c B ++
- **Isolated Paget's disease of the NAC:**
  - **Surgery must achieve R0** 1c B ++
  - **Surgical resection only, no adjuvant radiotherapy** 4 D ++
  - **Sentinel-node excision (SNE)** 2b B --

# Borderline and Malignant Phyllodes Tumor

- **Differential diagnosis may be problematic on core biopsy**
- **In-Breast recurrence relatively frequently seen (10 - 30%)**
- **Distant metastasis relatively rare (< 10%) and almost exclusively seen in malignant phyllodes tumor.**

<u>Feature</u>	<u>Frequency</u>
Grading	Benign PT (75%) Borderline PT (16%) Malignant PT (9%)
Median age on diagnosis	Benign PT: 39 J. Borderline PT: 45 J. Malignant PT: 47 J.
Local recurrence	Benign PT: 10 - 17% Borderline PT: 14 - 25% Malignant PT: 23 - 30%



# Borderline and Malignant Phyllodes Tumor Diagnosis

	Oxford / AGO LOE / GR		
➤ <b>Mammography, sonography</b>	<b>3</b>	<b>C</b>	<b>++</b>
➤ <b>Diagnosis on core biopsy, grading on resection specimen</b>	<b>3</b>	<b>C</b>	<b>++</b>
➤ <b>Breast MRI</b>	<b>3</b>	<b>C</b>	<b>+/-</b>
➤ <b>Staging only malignant PT (CT thorax, skeletal system)</b>	<b>5</b>	<b>D</b>	<b>++</b>

# Borderline and Malignant Phyllodes Tumor Surgery

Oxford / AGO  
LOE / GR

---

- **R0-Excision** 2b B ++
- **SNE / Axillary dissection when cN0** 4 C - -
- **Treatment of local recurrence**
  - **R0 resection or simple mastectomy** 4 C ++

© AGO e. V.  
in der DGGG e.V.  
sowie  
in der DKG e.V.

Guidelines Breast  
Version 2017.1

[www.ago-online.de](http://www.ago-online.de)

Further  
Information

References

# Borderline and Malignant Phyllodes Tumor Adjuvant Therapy

	Oxford / AGO LOE / GR		
➤ <b>Adjuvant radiotherapy</b>	4	C	--
➤ <b>If T ≥ 2 cm (BCT) or T ≥ 10 cm (mastectomy)</b>	2b	C	+/-
➤ <b>Systemic adjuvant therapy (chemo, endocrine)</b>	4	C	--
➤ <b>Treatment of local recurrence</b>			
➤ <b>R0 resection or simple mastectomy</b>	4	C	++
➤ <b>Radiotherapy, chemotherapy after R1 resection</b>	4	C	+/-
➤ <b>Distant metastases (very rare)</b>			
➤ <b>Treatment like soft tissue sarcomas</b>	4	C	++

# Sarcomas of the Breast

- **Not infrequently associated with familial syndromes (Li-Fraumeni, familial adenomatous polyposis, neurofibromatosis type 1)**
- **Primary sarcomas: angiosarcoma, undifferentiated sarcoma, leiomyosarcoma, liposarcoma, osteosarcoma**
- **Secondary malignancies of the breast:**
  - **Radiotherapy-Associated Angiosarcoma**
  - **Breast Implant Associated Large-Cell Anaplastic Lymphoma (BI-ALCL)**
- **Rare: intramammary sarcoma metastases**
- **Staging: TNM (UICC) or AJCC scheme of the soft tissue sarcoma analogous to sarcoma of the breast**
- **Grading: Analogous to the FNCLCC system for sarcoma or according to Rosen (1988) for angiosarcomas**

# Primary Angiosarcoma of the Breast

- **Most common primary sarcoma of the breast**
- **Young age (median: 24 - 46 years)**
- **Indistinct tumor borders**
- **Large tumor (median: 5 - 7 cm)**
- **Uncharacteristic findings on mammography and sonography**
- **High local recurrence risk, even after mastectomy**
- **More unfavorable prognosis than other primary sarcoma of the breast**

© AGO e. V.  
in der DGGG e.V.  
sowie  
in der DKG e.V.

Guidelines Breast  
Version 2017.1

[www.ago-online.de](http://www.ago-online.de)

Further  
Information

References

# Primary Angiosarcoma of the Breast\*

## Diagnosis

	Oxford / AGO LOE / GR		
➤ <b>Mammography, sonography to determine extent of disease</b>	3a	C	--
➤ <b>Preoperative MRI to determine the extent of disease</b>	3a	C	++
➤ <b>Diagnosis by core biopsy</b>	3a	C	++
➤ <b>Diagnosis by FNB</b>	3a	C	--
➤ <b>Staging (CT thorax &amp; abd.; angiosarcoma: MRI brain)</b>	4	D	++
➤ <b>Prognostic factors: size, grade, margins</b>	3a	C	++

\*Therapy in specialized centres recommended

# Primary Angiosarcoma of the Breast\*

## Therapy

- **Surgery with wide clear margins,  
mostly as mastectomy**
  - **Breast-conserving therapy**
- **SNB or axillary dissection if cN0**
- **Adjuvant chemotherapy  
(anthracycline/taxane-based)**
- **Adjuvant radiotherapy if high risk  
(size > 5 cm, R1)**

Oxford / AGO  
LOE / GR

---

3a C ++

3a C -

3a C --

4 C +/-

4 C +/-

# Secondary (Radiotherapy-associated) Angiosarcoma of the Breast



© AGO e. V.  
in der DGGG e.V.  
sowie  
in der DKG e.V.

Guidelines Breast  
Version 2017.1

- **Cumulative incidence of radiotherapy-associated sarcoma: 3.2 per 1,000 after 15 years**
  
- **Clinical presentation**
  - > 5 years after BCT or mastectomy with irradiation
  - usually intracutaneously or subcutaneously in the irradiation area with livid discoloration
  - multiple foci
  - most often in advanced stages (II - III)
  - metastases mostly pulmonary
  - lymph node metastasis possible
  
- **Prognosis is more unfavorable than in non-radiotherapy-associated sarcoma**
  
- **Survival after 5 years: 15%**

[www.ago-online.de](http://www.ago-online.de)

Further  
Information

References

**FORSCHEN  
LEHREN  
HEILEN**



# Secondary Angiosarcoma of the Breast Therapy

Oxford / AGO  
LOE / GR

- **Secondary mastectomy**
- **Adjuvant chemotherapy (anthracycline/taxane-based)**
- **Adjuvant radiotherapy if high risk (size > 5 cm, R1)**
- **Regional hyperthermia (to improve local control) plus chemotherapy and/or radiotherapy**

**3a C ++**

**2b B +/-**

**2b B +/-**

**2b B +/-**

# Angiosarcoma of the Breast

## Treatment of Local Recurrence and Metastases

Oxford / AGO  
LOE / GR

### Treatment of Local Recurrence:

- **R0 resection**
- **Radiotherapy, chemotherapy after R1 resection**

4 C ++

4 C +/-

### Distant Metastases / Unresectable Tumors:

- **Treatment like soft tissue sarcomas**
- **Paclitaxel weekly / liposomal doxorubicin (in angiosarcoma)**
- **Antiangiogenic treatment (e.g. in angiosarcoma)**

4 C ++

2b B +

4 C +/-

# Breast Implant-Associated Anaplastic Large-Cell Lymphoma (BIA-ALCL)

© AGO e. V.  
in der DGGG e.V.  
sowie  
in der DKG e.V.

Guidelines Breast  
Version 2017.1

- **Rare, estimated annual incidence <1 per 100,000 women with implants (median age 54 years)**
- **Occurrence predominantly of textured implants**
- **5-year OAS 89%**
- **Interval for lymphoma diagnosis: 8 years (median)**
- **Clinical presentation**
  - **Effusion only (60%)**
  - **Mass only (17%)**
  - **Effusion and mass (20%)**
- **Histological: CD30 + / ALK-T cell lymphoma**
- **Reporting obligation as SAE according to § 3 MPSV to the BfArM**

[www.ago-online.de](http://www.ago-online.de)

Further  
Information

References

# Breast Implant-Associated Anaplastic Large-Cell Lymphoma (BIA-ALCL) - Diagnosis -

	<u>Oxford / AGO LOE / GR</u>		
➤ <b>Sonography (for newly occurring seromas 1 year after implant placement, tumor mass)</b>	<b>5</b>	<b>D</b>	<b>++</b>
➤ <b>Breast MRI on confirmation of the diagnosis</b>	<b>5</b>	<b>D</b>	<b>++</b>
➤ <b>Nodal status, PET-CT, bone marrow biopsy</b>	<b>5</b>	<b>D</b>	<b>++</b>
➤ <b>Cytology of effusion (for newly occurring seromas 1 year after implant placement) with requisition "r/o BIA-ALCL"</b>	<b>5</b>	<b>D</b>	<b>++</b>
➤ <b>Lymphoma diagnosis on resection specimen and histological staging (acc. to Clemens 2016)</b>	<b>5</b>	<b>D</b>	<b>++</b>
➤ <b>Documentation of the implant (manufacturer, size, filling, surface, batch number)</b>	<b>5</b>	<b>D</b>	<b>++</b>

# Breast Implant-Associated Anaplastic Large-Cell Lymphoma (BIA-ALCL) - Treatment -



Oxford / AGO  
LOE / GR

- |   |                |
|---|----------------|
| ➤ <b>Implant removal and complete capsulectomy including tumor removal</b>                          | <b>3a C ++</b> |
| ➤ <b>Removal of suspicious lymph nodes, no routine sentinel-node biopsy, no axillary dissection</b> | <b>4 D ++</b>  |
| ➤ <b>Polychemotherapy (e.g., CHOP) when extracapsular tumor infiltration</b>                        | <b>4 D +</b>   |
| ➤ <b>Radiation for unresectable tumors or R1</b>  | <b>5 D +/-</b> |
| ➤ <b>Reconstruction after 1 year disease-free interval</b>  | <b>5 D +</b>   |

© AGO e. V.  
in der DGGG e.V.  
sowie  
in der DKG e.V.

Guidelines Breast  
Version 2017.1

www.ago-online.de

Further  
Information

References

FORSCHEN  
LEHREN  
HEILEN

# Breast Implant-Associated Anaplastic Large-Cell Lymphoma (BIA-ALCL) - Summary of the management (acc. to Noah 2017) -

© AGO e. V.  
in der DGGG e.V.  
sowie  
in der DKG e.V.

Guidelines Breast  
Version 2017.1

www.ago-online.de

Further  
Information

References

FORSCHEN  
LEHREN  
HEILEN

